Skip to search formSkip to main contentSkip to account menu

Avosentan

Known as: 2-Pyridinesulfonamide, N-(6-methoxy-5-(2-methoxyphenoxy)-2-(4-pyridinyl)-4-pyrimidinyl)-5-methyl-, 5-methylpyridine-2-sulfonic acid (6-methoxy-5-(2-methoxyphenoxy)-2-(pyridin-4-yl)pyrimidin-4-yl)amide 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

PyridinesPyrimidines

Narrower (1)

SPP301

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Diabetic nephropathy: Renoprotective effects of pentoxifylline in the PREDIAN trial
The PREDIAN trial investigated the renoprotective effects of pentoxifylline, in addition to renin–angiotensin system blockade, in… 
2011
2011
Novel Drug Treatment for Diabetic Nephropathy
2010
2010
Endothelin receptor antagonists in proteinuric renal disease: every rose has its thorn.
When Yanagisawa et al. 1 first identified endothelin (ET), a novel polypeptide vasoconstrictor for which numerous other functions… 
2010
2010
Endothelin Receptor Antagonists in Diabetic Nephropathy
Diabetic nephropathy (DN) is the leading cause of end-stage renal disease and affects an estimated 150 million people worldwide… 
2009
2009
Absolute bioavailability and pharmacokinetics of avosentan in man.
OBJECTIVE Avosentan is a potent, selective endothelin A receptor blocker. The pharmacokinetics of avosentan were investigated in… 
2008
2008
Influence of food intake on the pharmacokinetics of avosentan in man.
OBJECTIVE Avosentan is a potent, selective endothelin A receptor blocker. The effect of food intake on the pharmacokinetics of… 
2007
2007
Pharmaceutical composition using aliskiren and avosentan
The present invention relates to a pharmaceutical composition and method of achieving a therapeutic effect including, but not… 
2007
2007
Pharmaceutical compositions using aliskiren and avosentan
The present invention is allowed (i) SPP100 / aliskiren or a combination thereof and a pharmaceutically acceptable salt thereof… 
2007
2007
A pharmaceutical composition comprising the aliskiren and avosentan
1. A pharmaceutical composition comprising (1) SPP100 / aliskiren or a pharmaceutically acceptable salt thereof, (2) SPP301… 
2005
2005
Avosentan reduces proteinuria in diabetic nephropathy
  • 2005
  • Corpus ID: 195150231
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)